2.18
Sera Prognostics Inc stock is traded at $2.18, with a volume of 6,691.
It is up +1.87% in the last 24 hours and up +2.35% over the past month.
Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
See More
Previous Close:
$2.14
Open:
$2.12
24h Volume:
6,691
Relative Volume:
0.12
Market Cap:
$85.33M
Revenue:
$81,000
Net Income/Loss:
$-31.93M
P/E Ratio:
-3.2315
EPS:
-0.6746
Net Cash Flow:
$-26.35M
1W Performance:
-1.80%
1M Performance:
+2.35%
6M Performance:
-30.35%
1Y Performance:
-33.94%
Sera Prognostics Inc Stock (SERA) Company Profile
Name
Sera Prognostics Inc
Sector
Industry
Phone
(801) 990-0520
Address
2749 E. PARLEYS WAY, SALT LAKE CITY
Compare SERA vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
SERA
Sera Prognostics Inc
|
2.18 | 83.77M | 81,000 | -31.93M | -26.35M | -0.6746 |
|
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
Sera Prognostics Inc Stock (SERA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Initiated | Jefferies | Buy |
| Mar-30-22 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | Oppenheimer | Outperform |
| Oct-15-21 | Resumed | Cowen | Outperform |
Sera Prognostics Inc Stock (SERA) Latest News
Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Up 54.2% in March - MarketBeat
Aug Catalysts: How liquid is Sera Prognostics Inc stock2026 Winners & Losers & Intraday High Probability Alerts - baoquankhu1.vn
Sera Prognostics (SERA) upgraded to buy: What does it mean for the stock? - MSN
Investment Report: Can Sera Prognostics Inc lead its sector in growthShare Buyback & Consistent Profit Alerts - baoquankhu1.vn
Hedge Fund Bets: How does Sera Prognostics Inc perform in inflationary periodsTrade Risk Summary & Weekly Top Performers Watchlists - baoquankhu1.vn
Swing Trade: What is Sera Prognostics Incs valuation compared to sectorDollar Strength & Smart Money Movement Tracker - baoquankhu1.vn
Sera Prognostics (NASDAQ:SERA) and Basel Medical Group (NASDAQ:BMGL) Head to Head Survey - Defense World
Can Sera Prognostics Inc lead its sector in growthEarnings Trend Report & Reliable Price Breakout Alerts - baoquankhu1.vn
Sera Prognostics outlines accelerated Medicaid pilot expansion to 13 states as commercialization momentum builds - MSN
Sera Prognostics (SERA) Raised to Buy: What Are the Implications for Its Shares? - bitget.com
Sera Prognostics (SERA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Fundamentals Check: How does Sera Prognostics Inc perform in inflationary periods2026 Retail Activity & Weekly High Return Forecasts - baoquankhu1.vn
Short Covering: What is Sera Prognostics Incs valuation compared to sectorWeekly Trade Report & Risk Managed Investment Entry Signals - baoquankhu1.vn
Sera Prognostics Q4 2025 Earnings Call Transcript - AOL.com
Market Pulse: Will Sera Prognostics Inc outperform tech stocksPortfolio Risk Report & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Robert Harrison sells SERA shares under 10b5-1 plan (SERA) - Stock Titan
Market Outlook: Whats the beta of Sera Prognostics Inc stockChart Signals & Safe Swing Trade Setups - baoquankhu1.vn
Sera Prognostics outlines plan to expand partner programs to 15–17 states by year-end 2026 while maintaining cash runway through 2028 - MSN
History Review: Is Sera Prognostics Inc stock a value trapPortfolio Return Report & Real-Time Stock Entry Alerts - baoquankhu1.vn
Sera Prognostics, Inc. (SERA) reports Q4 loss, lags revenue estimates - MSN
What is Dogwood Therapeutics Incs book value per shareMarket Trend Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Bull Bear: Should I hold or sell Sera Prognostics Inc nowMarket Activity Recap & Weekly Breakout Watchlists - baoquankhu1.vn
Gains Report: Is Sera Prognostics Inc stock undervalued right nowNew Guidance & AI Based Buy and Sell Signals - baoquankhu1.vn
SERA SEC FilingsSera Prognostics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2025 Earnings Call Transcript - Insider Monkey
Sera Prognostics (NASDAQ: SERA) opens $40M ATM sales agreement with William Blair - Stock Titan
Sera Prognostics Earnings Call: Data-Rich, Revenue-Light - TipRanks
Sera Prognostics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Sera Prognostics Reports 2025 Financial Results: PRIME Study Validates PreTRM® Test, Expands U.S. and EU Commercialization, Secures $57.5M Financing 1 - Minichart
Sera Prognostics 2025 Annual Report: Innovative Biomarker Tests and Predictive Analytics for Pregnancy Care - Minichart
Sera Prognostics Inc (SERA) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... By GuruFocus - Investing.com Canada
Sera Prognostics Q4 Earnings Call Highlights - MarketBeat
Sera Prognostics 2025 Review: Commercialization and PreTRM ProgressNews and Statistics - IndexBox
Earnings call transcript: Sera Prognostics Q4 2025 results show EPS beat, revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Sera Prognostics Q4 2025 results show EPS beat, revenue miss - Investing.com Canada
SERA: PRIME study results and payer engagement drive commercial momentum amid disciplined financials - TradingView
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance Singapore
Sera Prognostics earnings beat by $0.03, revenue fell short of estimates - Investing.com Canada
Sera Prognostics Inc. (NASDAQ:SERA) Reports Q4 Revenue Miss, Narrower Loss - ChartMill
Stock Issuance Plan Details: Biotechnology company Sera Prognostics, Inc. (NASDAQ: SERA) announces the submission of a mixed shelf registration statement, planning to periodically issue Class A common stock in the future, with a total fundraising amount - Bitget
Sera Prognostics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Sera Prognostics 2025 10-K: Revenue $0.08M, EPS $(0.67) - tradingview.com
SERA: PRIME Study validated PreTRM® Test, commercial expansion advanced, and cash runway secured - TradingView
Sera Prognostics (NASDAQ: SERA) outlines PreTRM strategy and pregnancy diagnostics pipeline - Stock Titan
Sera Prognostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Sera Prognostics (SERA) posts 2025 loss but holds $95.8M cash runway - Stock Titan
BRIEF-Sera Prognostics Q4 Revenue USD 10 Thousand - TradingView
SERA PROGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS - PR Newswire
Geopolitics Watch: Is Sera Prognostics Inc in a long term uptrend2026 Reactions & Community Trade Idea Sharing Platform - baoquankhu1.vn
Sera Prognostics, Inc. (SERA) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
Sera Prognostics Inc Stock (SERA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sera Prognostics Inc Stock (SERA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lindgardt Zhenya | Chief Executive Officer |
Mar 10 '26 |
Sale |
1.90 |
22,639 |
43,014 |
741,287 |
| Lindgardt Zhenya | Chief Executive Officer |
Mar 11 '26 |
Sale |
2.04 |
2,973 |
6,065 |
738,314 |
| Kearney Paul | Chief Data Officer |
Mar 11 '26 |
Sale |
2.04 |
1,396 |
2,848 |
163,961 |
| Jackson Benjamin | General Counsel |
Mar 11 '26 |
Sale |
2.04 |
1,027 |
2,095 |
114,720 |
| Harrison Robert Gardner | Chief Information Officer |
Mar 11 '26 |
Sale |
2.04 |
716 |
1,461 |
76,712 |
| Boniface John J. | Chief Scientific Officer |
Mar 11 '26 |
Sale |
2.04 |
1,517 |
3,095 |
145,842 |
| Aerts Austin | Chief Financial Officer |
Mar 10 '26 |
Sale |
1.90 |
6,069 |
11,531 |
265,471 |
| Aerts Austin | Chief Financial Officer |
Mar 11 '26 |
Sale |
2.04 |
1,019 |
2,079 |
264,452 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):